Menu
Search
|

Menu

Close
X

Incyte Corp INCY.OQ (NASDAQ Stock Exchange Global Select Market)

65.04 USD
-0.00 (-0.00%)
As of Oct 17
chart
Previous Close 65.04
Open 64.91
Volume 522,016
3m Avg Volume 570,499
Today’s High 65.47
Today’s Low 64.10
52 Week High 117.95
52 Week Low 60.22
Shares Outstanding (mil) 210.65
Market Capitalization (mil) 24,161.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY18
904
FY17
1,536
FY16
1,106
FY15
754
EPS (USD)
FY18
0.049
FY17
-1.558
FY16
0.538
FY15
-0.021
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.73
Price to Sales (TTM)
vs sector
18.49
5.82
Price to Book (MRQ)
vs sector
22.97
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
2.28
16.96
LT Debt to Equity (MRQ)
vs sector
2.28
12.63
Return on Investment (TTM)
vs sector
-11.99
14.31
Return on Equity (TTM)
vs sector
-23.24
16.04

EXECUTIVE LEADERSHIP

Herve Hoppenot
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $966,505.00
Bonus: --
David Gryska
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $569,421.00
Bonus: --
Reid Huber
Executive Vice President, Chief Scientific Officer, Since 2014
Salary: $493,534.00
Bonus: --
Paula Swain
Executive Vice President - Human Resources, Since 2002
Salary: $343,346.00
Bonus: --
Barry Flannelly
Executive Vice President and General Manager - US, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1801 Augustine Cut off
WILMINGTON   DE   19803-4404

Phone: +1302.4986700

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

SPONSORED STORIES